Prucalopride

(Motegrity®)

Prucalopride

Drug updated on 5/17/2024

Dosage FormTablet (oral; 1 mg, 2 mg)
Drug ClassSerotonin-4 receptor agonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of chronic idiopathic constipation (CIC) in adults.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Prucalopride (Motegrity) is indicated for the treatment of chronic idiopathic constipation (CIC) in adults. It has demonstrated efficacy in reducing time to stool post gastrointestinal surgery, with a mean decrease of 36.82 hours compared to placebo.
  • Eight systematic reviews/meta-analyses provided a comprehensive analysis comparing Motegrity with other drugs in terms of safety and effectiveness for various gastrointestinal conditions including CIC, postoperative ileus, and gastroparesis.
  • In treating gastroparesis, prucalopride showed statistically significant improvements in Gastroparesis Cardinal Symptom Index scores and gastric emptying time among patients with both diabetic and idiopathic gastroparesis compared to placebo; however, it was associated with higher total adverse events than placebo, indicating a need for careful consideration of its adverse effect profile.
  • For chronic idiopathic constipation (CIC), studies suggested that a 1 mg dose might offer safer outcomes while being efficacious as well. However, long-term efficacy remains unclear due to the short duration of trials, which were mostly between 4-12 weeks.
  • When used by elderly patients suffering from constipation, laxatives like prucalopride have shown safe usage within three months, but more robust research is needed given the low quality of the included studies on this demographic group.
  • Adding prucalopride to bowel preparation solutions showed no significant difference in preparation quality or adverse effects compared to traditional solutions, suggesting potential use cases beyond just CIC treatment such as maintaining efficacy while potentially reducing the volume required during colonoscopy preparations.

Product Monograph / Prescribing Information

Document TitleYearSource
Motegrity (prucalopride) Prescribing Information.2020Takeda Pharmaceuticals America, Inc., Lexington, MA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines